COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,441 Articles (22,835 medRxiv, 8,606 bioRxiv)

Most recent first Previous |  Page 699: Articles 6981-6990  | Next

Geospatial disparities in federal COVID-19 test-to-treat program
Smith, E. R., Oakley, E. M.
10.1101/2022.08.02.22278349 — Posted: 2022-08-03
Healthcare workers' worries and Monkeypox vaccine advocacy during the first month of the WHO Monkeypox alert: Cross-sectional survey in Saudi Arabia
Aljamaan, F., Alenezi, S., Alhasan, K., Saddik, B., Alhaboob, A., Altawil, E. S., Alshahrani, F., Alrabiaah, A., Alaraj, A., Alkriadees, K., Alshammari, Y., Alharbi, H., Jamal, A., Halwani, R., AlZamil, F., Al-Subaie, S., Barry, M., Memish, Z. A., Al-Tawfiq, J. A., Temsah, M. H.
10.1101/2022.08.02.22278317 — Posted: 2022-08-03
COVID-19 illness, SARS-CoV2 infection, and subsequent suicidal ideation in the French nationwide population-based EpiCov cohort : a propensity score analysis of more than 50,000 individuals.
Davisse-Paturet, C., Orri, M., Legleye, S., Florence, A.-M., Hazo, J.-B., WARSZAWSKI, J., Falissard, B., Geoffroy, M.-C., Melchior, M., Rouquette, A.
10.1101/2022.08.02.22278311 — Posted: 2022-08-03
The health impact of long COVID during the 2021-2022 Omicron wave in Australia: a quantitative burden of disease study
Howe, S., Szanyi, J., Blakely, T.
10.1101/2022.08.01.22278219 — Posted: 2022-08-03
DNA Origami Presenting the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Response
Oktay, E., Alem, F., Hernandez, K., Narayanan, A., Veneziano, R.
10.1101/2022.08.02.502186 — Posted: 2022-08-02
UVC-based air disinfection system for rapid inactivation of SARS-CoV-2 present in the air
Garg, H., Ringe, R. P., Das, S., Parkash, S., Thakur, B., Delipan, R., Kumar, A., Kulkarni, K. S., Bansal, K., Patil, P. B., Alam, T., Balam, N. B., Meena, C. S., Thakur, K. G., Kumar, A., Kumar, A.
10.1101/2022.08.02.502427 — Posted: 2022-08-02
Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
Muik, A., Lui, B. G., Bacher, M., Wallisch, A.-K., Toker, A., Finlayson, A., Krueger, K., Ozhelvaci, O., Grikscheit, K., Hoehl, S., Ciesek, S., Tuereci, O., Sahin, U.
10.1101/2022.08.02.502461 — Posted: 2022-08-02
NF-κB inhibitor alpha has a cross-variant role during SARS-CoV-2 infection in ACE2-overexpressing human airway organoids
Simoneau, C. R., Chen, P.-Y., Xing, G. X., Khalid, M. M., Meyers, N. L., Hayashi, J. M., Taha, T. Y., Leon, K. E., Ashuach, T., Fontaine, K. A., Rodriguez, L., Joehnk, B., Walcott, K., Vasudevan, S., Fang, X., Maishan, M., Schultz, S., Roose, J., Matthay, M. A., Sil, A., Arjomandi, M., Yosef, N., Ott, M.
10.1101/2022.08.02.502100 — Posted: 2022-08-02
Serological surveillance for wild rodent infection with SARS-CoV-2 in Europe
Bourret, V., Dutra, L., Alburkat, H., Maki, S., Lintunen, E., Wasniewski, M., Kant, R., Grzybek, M., Venkat, V., Asad, H., Pradel, J., Bouilloud, M., Leirs, H., Colombo, V. C., Sluydts, V., Stuart, P., McManus, A., Eccard, J. A., Firozpoor, J., Imholt, C., Nowicka, J., Goll, A., Ranc, N., Castel, G., Charbonnel, N., Sironen, T.
10.1101/2022.08.02.502439 — Posted: 2022-08-02
SARS-CoV-2 Omicron BA.1 and BA.2 are attenuated in rhesus macaques as compared to Delta
van Doremalen, N., Singh, M., Saturday, T., Yinda, K. C., Perez-Perez, L., Bohler, W. F., Weishampel, Z., Lewis, M., Schulz, J., Williamson, B., Meade-White, K., Gallogly, S., Okumura, A., Feldmann, F., Lovaglio, J., Hanley, P., Shaia, C., Feldmann, H., de Wit, E., Munster, V., Rosenke, K.
10.1101/2022.08.01.502390 — Posted: 2022-08-02

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).